Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)

More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) i...

Descripción completa

Detalles Bibliográficos
Autor principal: De Clercq, Erik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2007
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146830/
https://www.ncbi.nlm.nih.gov/pubmed/32288473
http://dx.doi.org/10.1016/S1075-8593(06)05002-7
_version_ 1783520291938369536
author De Clercq, Erik
author_facet De Clercq, Erik
author_sort De Clercq, Erik
collection PubMed
description More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies.
format Online
Article
Text
id pubmed-7146830
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-71468302020-04-10 Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES) De Clercq, Erik Adv Antivir Drug Des Article More than 40 compounds have been formally licensed for clinical use as antiviral drugs, and half of these are used for the treatment of HIV infections. The others have been approved for the therapy of herpesvirus (HSV, VZV, CMV), hepadnavirus (HBV), hepacivirus (HCV) and myxovirus (influenza, RSV) infections. New compounds are in clinical development or under preclinical evaluation, and, again, half of these are targeting HIV infections. Yet, quite a number of important viral pathogens (i.e. HPV, HCV, hemorrhagic fever viruses) remain in need of effective and/or improved antiviral therapies. Elsevier B.V. 2007 2007-09-02 /pmc/articles/PMC7146830/ /pubmed/32288473 http://dx.doi.org/10.1016/S1075-8593(06)05002-7 Text en Copyright © 2007 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
De Clercq, Erik
Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title_full Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title_fullStr Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title_full_unstemmed Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title_short Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
title_sort status presens of antiviral drugs and strategies: part ii: rna viruses (except retroviruses)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146830/
https://www.ncbi.nlm.nih.gov/pubmed/32288473
http://dx.doi.org/10.1016/S1075-8593(06)05002-7
work_keys_str_mv AT declercqerik statuspresensofantiviraldrugsandstrategiespartiirnavirusesexceptretroviruses

Ejemplares similares